Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$112.73 USD

112.73
3,508,682

+0.12 (0.11%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $112.69 -0.04 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day.

Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems

by Zacks Equity Research

Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day.

Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind

by Zacks Equity Research

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Here's How Much a $1000 Investment in Abbott Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.

Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.

Abbott (ABT) Just Overtook the 50-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Abbott (ABT) Stock Moves -0.42%: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $106.25, marking a -0.42% move from the previous day.

Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB

by Zacks Equity Research

Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with Surmodics.

Abbott (ABT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $101.86, moving +0.45% from the previous trading session.

Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers

by Zacks Equity Research

Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.

Sheraz Mian headshot

Top Stock Reports for Procter & Gamble, Bank of America & Abbott Laboratories

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT).

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NOBL

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $101.66, marking a -0.94% move from the previous day.

Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Abbott (ABT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $102.82, marking a +0.8% move from the previous day.

Abbott (ABT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $102 in the latest trading session, marking a +0.29% move from the prior day.

Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result

by Zacks Equity Research

Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Abbott (ABT) Expands in Electrophysiology With New FDA Nod

by Zacks Equity Research

Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.